Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Unicycive Therapeutics (UNCY) Operating Expenses (2020 - 2026)

Unicycive Therapeutics filings provide 3 years of Operating Expenses readings, the most recent being $9.3 million for Q4 2024.

  • On a quarterly basis, Operating Expenses rose 46.7% to $9.3 million in Q4 2024 year-over-year; TTM through Dec 2024 was $32.1 million, a 49.73% increase, with the full-year FY2025 number at $29.5 million, down 8.1% from a year prior.
  • Operating Expenses hit $9.3 million in Q4 2024 for Unicycive Therapeutics, up from $6.3 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $9.3 million in Q4 2024 to a low of $3.5 million in Q1 2022.
  • Median Operating Expenses over the past 3 years was $6.1 million (2023), compared with a mean of $6.0 million.
  • Biggest five-year swings in Operating Expenses: fell 8.72% in 2023 and later soared 88.72% in 2024.
  • Unicycive Therapeutics' Operating Expenses stood at $5.3 million in 2022, then rose by 18.55% to $6.3 million in 2023, then surged by 46.7% to $9.3 million in 2024.
  • The last three reported values for Operating Expenses were $9.3 million (Q4 2024), $6.3 million (Q3 2024), and $7.4 million (Q2 2024) per Business Quant data.